Medical disclaimer: This post covers published evidence on GLP-1 medications — not medical advice. Medication decisions belong with your doctor.
The Bottom Line: GLP-1 drugs like Ozempic produce real weight loss by suppressing appetite and slowing digestion. But they don’t change your metabolism.
When you stop, hunger returns, carbohydrate dependency is still there, and the Wilding et al. NEJM 2022 research data shows roughly two-thirds of lost weight returns within a year. The fix isn’t a longer course of medication.
It’s building the health foundations you need while you’re on the medication.
He lost 22 kilograms on semaglutide. Took him about eight months. His doctor was pleased. He looked different. He felt different.
(If you’re currently on a GLP-1 medication and weighing up whether to continue, I covered what men over 40 should know before and during GLP-1 treatment in a separate piece. This article is about what happens after.)
Then he stopped. Insurance ran out.
Three months later, 9 kilograms back. Six months later, 15. His hunger was back in a way that felt almost aggressive. He was eating the same things he’d always eaten – because his body still wanted exactly those things. Nobody had told him that was going to happen. And nobody had told him why.
He’s not an outlier. He’s the study data.
How do GLP-1 drugs like Ozempic cause weight loss?
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are GLP-1 receptor agonists. GLP-1 is a gut hormone your body releases after eating. It signals the hypothalamus to reduce appetite. It slows gastric emptying – food moves through your stomach more slowly, so you feel full for longer.
That’s the mechanism. The drug mimics a satiety signal and holds it there.
The result is a significant reduction in how much you eat. Not because you’ve changed what you want, or fixed anything upstream. Because the signal to eat is being pharmacologically suppressed.
Real weight loss follows. The clinical trials are solid. In the STEP 1 trial, participants lost an average of around 15% of body weight over 68 weeks of treatment. That’s significant. For a man carrying 30 extra kilograms, 15% is a real result.
The problem isn’t what GLP-1 drugs do. It’s what they don’t do.
What does the evidence show about weight regain after stopping Ozempic?
Wilding et al., published in the New England Journal of Medicine in 2022, followed participants from the STEP 1 trial for one year after stopping semaglutide. The finding was blunt: approximately two-thirds of the lost weight returned within 12 months of stopping the drug.
Two-thirds. In a year.
The authors’ explanation: the drug doesn’t produce lasting changes to the underlying physiology. Once you stop taking it, the biological signals driving appetite and fat storage return to their pre-treatment baseline.
This isn’t a rare outcome or a failure by the patients involved. It’s the expected result when you remove the suppression without changing what’s underneath it.
The drug companies don’t hide this. Some clinicians recommend staying on GLP-1 medications indefinitely. For some patients, that may be the right call clinically. But indefinite medication dependency is not weight management. It’s appetite management. There’s a difference.
Why does the weight come back when you stop taking Ozempic or Mounjaro?
The drug never addressed any of this.
Most men who are significantly overweight in their 40s and 50s got there through years of carbohydrate-heavy eating. Not because they lack self-control. Because the standard dietary advice they followed – eat plenty of whole grains, reduce fat, count calories – kept insulin elevated, and elevated insulin keeps fat locked in storage.
That creates carbohydrate dependency. The body becomes reliant on glucose as its primary fuel source. When blood glucose drops, hunger hits hard and fast. The body doesn’t pull fat out of storage efficiently. It signals for more carbohydrate.
GLP-1 drugs suppress that hunger signal. But they don’t fix the insulin dynamics underneath it. They don’t shift the body toward fat as fuel. The metabolic programming – carbohydrate dependency, insulin resistance – is intact the entire time you’re on the medication.
Stop the drug, and the suppression ends. Old hunger returns, full strength. Old food preferences return. The same metabolic environment that drove the original weight gain is still there, waiting.
The body doesn’t need to relearn bad habits. It never forgot them.
Whether you’re on a GLP-1 drug right now or still deciding, get your GLP-1 Foundations Score. The exit quiz shows you what’s actually happening in your metabolism, and what you’ll need to address before you come off the medication.
What do GLP-1s do to muscle mass during weight loss?
This part gets skipped over a lot. It shouldn’t.
When you lose weight in a caloric deficit while eating a high-carbohydrate diet, your body breaks down a mix of fat and muscle. Muscle is metabolically active tissue. Your resting metabolic rate – how many calories you burn doing nothing – is partly determined by how much of it you carry.
GLP-1 trial data consistently shows a significant proportion of weight lost on these medications is lean mass, not fat. Multiple analyses put lean tissue loss at 25-40% of total weight lost – the exact figure varies with diet and activity, but the direction doesn’t.
Lose 20 kilograms on semaglutide or tirzepatide with no resistance training and a carb-heavy diet. Put 14 of those kilograms back after stopping. You’ve potentially ended up with less muscle than when you started – and more fat as a percentage of your body weight.
A slower metabolism. A higher fat-to-muscle ratio. And all the hunger of a body that’s been chronically underfed.
This is why men who’ve used GLP-1 drugs and want to stay off them need more than just a different diet. They need to rebuild what was lost.
What is the alternative to GLP-1 drugs for long-term weight management?
The alternative is building the metabolic conditions that make appetite suppression a natural state, not a pharmaceutical one.
LCHF – low-carb, healthy-fat – removes the foods that drive chronic insulin elevation. Without the constant glucose spikes, insulin drops. When insulin is low, fat storage switches off and fat burning switches on. The result is fat adaptation – the body running primarily on fat, with hunger that normalises naturally rather than being pharmacologically suppressed. The body gains access to its own stored energy in a way it can’t when carbohydrate dependency is running the show.
Jason Fung, Tim Noakes, Stephen Phinney – their research comes from different angles and lands in the same place every time. The appestat resets. Hunger normalises. Not because it’s being suppressed from outside, but because the metabolic signal has changed.
Fat-adapted men don’t experience the aggressive hunger that characterises carbohydrate dependency. They can go hours without food without their concentration collapsing or their mood dropping. Their bodies are running on a fuel source that doesn’t require constant refilling.
That appetite suppression is stable. It doesn’t depend on a prescription or a continuing injection. It’s a different metabolic state – one the body maintains because the underlying programming has changed.
Combined with resistance training to preserve and rebuild lean mass, this produces weight loss that holds. Not because willpower is higher. Because the physiology is different.
What does this look like in practice?
Mark was on the weight loss surgery waiting list when he came to me. 18 kilograms in 12 weeks. 20 kilograms total. He never had the surgery. The waiting list removed him.
Cameron is former elite military. 30 kilograms in 3 months. The discipline was already there. He just needed the right diet to match how hard he was willing to work.
Paul lost 20 kilograms in 12 weeks. That’s not the number I want you to look at. The number is 33 kilograms total – including 13 kilograms he maintained after the program ended. That 13 kilograms is the evidence of something that held. GLP-1 drugs can produce the first number. The post-program maintenance is what they don’t produce.
See these, and many more client results, here.
My own numbers: I’m 60. 65 kilograms. 15% body fat. Resting heart rate of 39. I’ve maintained this for 14 years. No medication. No hunger battles. A metabolically flexible body that runs efficiently on fat. I got there the same way I take clients – through LCHF and fat adaptation, applied consistently.
These results aren’t about genetics or willpower. They’re about getting the metabolic environment right.
The principle: if you used Ozempic or Mounjaro, here’s what to do
I’m not going to tell you that taking a GLP-1 drug was the wrong call. I don’t know your medical history. Your doctor does.
Here’s what I can tell you: if you used semaglutide or tirzepatide and lost weight, you’ve already done something most men haven’t. You know what a lighter body feels like. That’s not nothing.
But the drug gave you appetite suppression without metabolic reprogramming. Stop the drug and you’re back at the starting metabolic conditions. You’ve got a head start – the habit of eating less is established, even if your biology is trying to override it – but the window to use that head start closes as the weight returns.
The move is to replace pharmacological appetite suppression with physiological appetite suppression. Get into nutritional ketosis. Build fat adaptation. Do resistance work to recover the lean mass you may have lost. Don’t go back to the carbohydrate-heavy baseline that put the weight on in the first place.
You don’t need a longer course of medication. You need the metabolic foundation the medication never built.
Work with someone who’s already solved this
I’ve worked with 850 men globally over 14 years. Some have used GLP-1 drugs. Some were looking for an alternative. The approach is the same: fix the metabolic environment, build the lean mass, reset the appestat.
The results are on my site. If you’re done relying on a drug to manage your hunger and want to understand what the alternative looks like for your specific situation, start here.
Find out exactly what's keeping you stuck.
Frequently asked questions
What happens when you stop taking Ozempic?
The appetite suppression stops. Hunger comes back to where it was before you started – sometimes harder, because your body has been running at a deficit. If you haven’t shifted the metabolic conditions, the body defaults to the same fat-storage patterns as before. Wilding et al. (NEJM, 2022) found roughly two-thirds of weight lost on semaglutide returns within 12 months of stopping.
Why does Ozempic weight loss rebound happen?
GLP-1 drugs work by suppressing appetite and slowing gastric emptying. They don’t change how the body processes or stores fuel. They don’t fix insulin resistance or carbohydrate dependency. When the drug stops, the suppression stops with it. The same metabolic conditions that caused the original weight gain are still there.
Does semaglutide cause muscle loss?
Yes. Any weight loss in a caloric deficit loses some muscle alongside the fat, and GLP-1 medications are no exception – especially if you’re not doing resistance training throughout. Multiple analyses put lean tissue loss at 25-40% of total weight lost. That matters because your resting metabolic rate depends partly on how much muscle you carry. Less muscle, slower metabolism.
What is the best way to keep weight off after stopping Ozempic?
Shift to a low-carb, healthy-fat diet. That’s what reduces the chronic insulin elevation that’s been keeping fat stored. The body moves into fat adaptation – running primarily on fat as fuel, with hunger that normalises naturally. Add resistance training to rebuild the lean mass you likely lost. Together those two things fix the metabolic conditions the drug never touched.
How is LCHF different from Ozempic for weight loss?
Ozempic pharmacologically suppresses your appetite. LCHF changes the hormonal environment – specifically, it lowers insulin, which shifts the body from fat storage to fat burning. The appetite reduction from fat adaptation isn’t an external suppression. It’s the natural result of a different metabolic state. It doesn’t require a prescription and it doesn’t reverse when you stop.
References
- Wilding JPH, Batterham RL, Calanna S, et al.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725 - Wilding JPH, Batterham RL, Davies M, et al.
Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 - Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 - Aronne LJ, Sattar N, Horn DB, et al.
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity or overweight (SURMOUNT-4). JAMA. 2024.
https://jamanetwork.com/journals/jama/fullarticle/2812936 - Heymsfield SB, Gonzalez MC, Shen W, et al.
Weight loss composition is one-fourth fat-free mass: A critical review and critique of this widely cited rule. Obesity Reviews. 2014.
https://onlinelibrary.wiley.com/doi/10.1111/obr.12143 - Müller MJ, Bosy-Westphal A, Heymsfield SB.
Is there evidence for a set point that regulates body weight? F1000 Medicine Reports. 2010.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990627/ - Hall KD, Kahan S.
Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America. 2018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764193/
